FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-028								
Estimated average	hurdon								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

37 hours per response: 0.5

					,															
Name and Address of Reporting Person*  To be Delivered.						2. Issuer Name <b>and</b> Ticker or Trading Symbol MADRIGAL PHARMACEUTICALS,									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Taub Rebecca				INC. [ MDGL ]									X Direc		ector 10% C		% Owner			
(Last) (First) (Middle)				111	IIVC. [ MDGL ]									X	X Officer (give title below)			ner (specify ow)		
					3 D	Date of Earliest Transaction (Month/Day/Year)									Chief	Chief Medical Officer, EVP R&D				
C/O MADRIGAL PHARMACEUTICALS, INC.					06/11/2018												,			
200 BARR HARBOR DRIVE, SUITE 400																				
(Street)					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
WEST PA 19428														X		m filed by One Reporting Person				
CONSHOHOCKEN														Form filed by More than One Reporting Person						
(City)	(St	ate) (	Zip)																	
		Tabl	e I - No	n-Deriva	ative	Sec	uritie	s Acc	quired	, Dis	posed o	f, oı	r Ben	eficia	ally (	Owne	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day)				Execution Date,		xecution Date, any		Transaction Disposed Code (Instr.		ies Acquired (A) o Of (D) (Instr. 3, 4			and 5) Secu Bene		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect			
							Code	v	Amount		(A) or (D)	Price		Transaction(s) (Instr. 3 and 4)			(1130.4)			
Common Stock 06/11/2					/2018				S		73,526		A	\$287	7.46	655,540		I	By SQN, LLC <sup>(1)</sup>	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transaction Code (Instr. 8)		n of		6. Date Exercisab Expiration Date (Month/Day/Year)		te	Amo Sec Und Deri Sec	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			vative irity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)		Date Exercisa		Expiration Date	Title	or Nu of	mber ares						

## **Explanation of Responses:**

1. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

/s/ Rebecca Taub

06/12/2018

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.